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Background: Central hypothyroidism (CeH) is a rare condition affecting approximately
1:16 000- 100 000 individuals. Congenital forms can harm normal development if not
detected and treated promptly. Clinical and biochemical diagnosis, especially of isolated
CeH, can be challenging. Cases are not usually detected in neonatal screening, which, in
most countries, is focused on detection of the more prevalent primary hypothyroidism.
Until now, five genetic causes for isolated CeH have been identified. Here we aimed to
identify the genetic cause in two brothers with impaired growth diagnosed with CeH at the
age of 5 years. We further evaluated the candidate gene variants in a large genetic
database.
Methods: Clinical and biochemical characterization together with targeted next-
generation sequencing (NGS) was used to identify the genetic cause in a family of two
brothers presenting with CeH. Screening of insulin receptor substrate 4 (IRS4) variants
was carried out in the FinnGen database.
Results: A novel monoallelic frameshift mutation c.1712_1713insT, p.Gly572Trp fs*32 in
the X-linked IRS4 gene was identified by NGS analysis in both affected males and
confirmed using Sanger sequencing. Their mother was an unaffected carrier. In addition to
the declined growth at presentation, central hypothyroidism and blunted TRH test, no
other phenotypic alterations were found. Diagnostic tests included head MRI, thyroid
imaging, bone age, and laboratory tests for thyroid autoantibodies, glucose, insulin and
glycosylated hemoglobin levels. Examination of the IRS4 locus in FinnGen (R5) database
revealed the strongest associations to a rare Finnish haplotype associated with thyroid
disorders (p = 1.3e-7) and hypothyroidism (p = 8.3e-7).
Conclusions: Here, we identified a novel frameshift mutation in an X-linked IRS4 gene in
two brothers with isolated CeH. Furthermore, we demonstrate an association of IRS4n.org May 2021 | Volume 12 | Article 6581371
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the role of IRS4 in isolated central hypothyroidism.Keywords: insulin receptor substrate 4, IRS4, central hypothyroidism, thyroid disorders, genetic screening,
FinnGen, congenital hypothyroidismINTRODUCTION
Central hypothyroidism (CeH) is defined as a reduced thyroid
hormone secretion from an otherwise functional thyroid gland
due to diminished stimulation of the gland. Reduced stimulation
can result either from an impaired secretion of thyroid
stimulating hormone (TSH) from the anterior pituitary,
defective secretion or action of hypothalamic thyrotropin
releasing hormone (TRH), or both (1).
Central hypothyroidism is rarely an isolated defect, but most
often appears congenitally as a part of panhypopituitarism
affecting also gonadotropin, adrenocorticotrophic hormone
(ACTH) or growth hormone secretion. Panhypopituitarism
can be potentially life-threatening, primarily because of severe
hypoglycemia. The exact prevalence of CeH is unknown, but the
presentation of genetic forms shows a peak in childhood,
whereas other forms due to pituitary lesions are typical later in
adulthood (2). Estimations of CeH prevalence vary between 1:16
000-100 000 individuals (3, 4). Overall, CeH has been reported to
be equally distributed in both sexes. However, known X-linked
forms suggest a male predominance (2). In addition to the
genetic etiology of isolated central hypothyroidism, impairing
only TSH secretion, CeH has been described in patients with
pituitary tumors, trauma, radiation therapy, diabetes mellitus or
it may be idiopathic (5). Genetic defects in pituitary transcription
factors can lead to CeH, but are usually associated also with other
hormonal defects (1). Isolated TSH deficiency covers
approximately 20% of all CeH cases (2). Inherited isolated
CeH has been demonstrated to be caused by mutations in
thyroid releasing hormone receptor (TRHR), thyroid stimulating
hormone beta subunit (TSHB), immunoglobulin superfamily
member 1 (IGSF1), transducin (beta)-like 1X-linked (TBL1X)
and more recently, in insulin receptor substrate 4 (IRS4) genes
(6). Among these genes TRHRmutations has been shown to lead
to blunted TSH response to TRH, growth retardation and obesity
during childhood (7). Furthermore, TSHB mutations are
characterized by neonatal onset of low TSH, high glycoprotein
hormone alpha-subunit levels and pituitary hyperplasia, which is
reversible with thyroxine treatment (8). Mutations in both IGSF1
and TBL1X can lead to X-linked isolated CeH, but IGSF1
mutations are also associated with low PRL, variable GH
defic iency , metabol ic syndrome, and postpuber ta l
macroorchidism (9). In addition, the mutations in the TBL1X
can also lead to impaired hearing (10).
Here we describe a genetic, biochemical and clinical
characterization of a family with two brothers diagnosed with
CeH at the age of 5 years and shown to carry a novel frameshift
mutation in the IRS4 gene. Furthermore, we evaluate the overall
occurrence of IRS4 variants and their association to other clinical
phenotypes in a large national genetic database.n.org 2MATERIALS AND METHODS
Study Participants
The study participants were recruited to the study by a pediatric
endocrinologist, and they and their parents signed a written
consent. The Ethics Committee of the Hospital District of
Southwest Finland approved the study (108/180/2010).
The clinical examinations were performed by a pediatrician
(SK) and thyroid ultrasound, head MRI and bone age by the
pediatric radiologists. Laboratory tests were done at the Turku
University Hospital Laboratory, except for the IGF-1 test, which
was performed in the Islab-laboratory (Kuopio, Finland).
Umbilical serum TSH (uS-TSH), serum TSH, free T4 (fT4),
insulin and cortisol concentrations were determined with the
Cobas e801 immunoassay analyzer (Roche Diagnostics,
Rotkreuz, Switzerland). Serum cholesterol (HDL cholesterol,
LDL cholesterol and triglycerides) were determined with the
Cobas c702 chemistry analyzer (Roche Diagnostics). Serum
glycosylated hemoglobin (HbA1c) was determined with the
Cobas c501 immunoturbidimetric assay (Roche Diagnostics).
Serum IGF-1 concentrations were determined with the Liaison
XL chemiluminescence analyzer (DiaSorin S.p.A, Saluggia, Italy).
Growth data were collected from the hospital records based on
measurements performed at the visits using stabilized and
calibrated scale and wall mounted Harpenden Stadiometer
(Holtain Limited, Crosswell, Crymych, Pembs., UK) with ±0.1
cm precision.
TRH Stimulation Test
At the start of the TRH stimulation test, non-fasting serum TSH
concentrations were measured. A bolus of 7 mg/kg of TRH
(Ferring Pharmaceuticals, Saint-Prex, Switzerland) was given
intravenously, and subsequently the serum TSH concentrations
were measured at 20 and 60 minutes.
Genetic Analysis
Genetic analyses were performed on DNA extracted from
peripheral blood. Amplification of target region was performed
with PCR using AmpliTaq Gold 360 (ThermoFisher Scientific,
Waltham, MA, USA) according to the manufacturer’s protocol
in the Veriti 96-Well Thermal Cycler (Applied Biosystems,
Foster City, CA, USA). Primers used are listed in the
Supplemental Table 2. For the index patient an NGS-based
targeted panel was performed with Sophia Genetics custom
clinical exome solution (Sophia Genetics, Boston, MA, USA)
and Illumina sequencing (Illumina, San Diego, CA, USA),
including 4400 known disease-causing genes. NGS libraries
were prepared using a hybrid capture method according to the
manufacturer´s protocol (Sophia Genetics CCE_A_v1). DNA
was sequenced with NextSeq sequencer (Illumina, San Diego,May 2021 | Volume 12 | Article 658137
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variation was visually inspected using the Integrative Genomics
Viewer (11). Bioinformatic analysis and annotation was focused
on the following candidate gene panel for CeH: HESX1, IGSF1,
IRS4, LEPR, LHX3, LHX4, OTX2, POU1F1, PROP1, SOX3,
TBL1X, TRHR and TSHB.
Confirmation of the IRS4 mutation and its segregation was
tested with PCR and Sanger sequencing. The primer sequences
and PCR conditions are listed in the Supplementary Materials.
Sequencing reactions were performed by using BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems).
Sequencing was performed with the ABI3500xl Dx (Applied
Biosystems) and chromatograms were analyzed using
Sequencher v5. (Gene Codes Corporation, MI, USA). The
alignment of WT and mutated IRS4 sequences was performed
using the Clustal O (1.2.4) multiple sequence alignment tool (12).
IRS4 Variant Analysis in the
FinnGen Database
The FinnGen project has been approved by the Ethical Review
Board of the Hospital District of Helsinki and Uusimaa with the
protocol Nr. HUS/990/2017. The FinnGen data release 5 was used.
Detailed information about of the different releases is described on
the FinnGen’s website1. Release 5 comprises of data from 218 792
Finnish participants with disease endpoints2 constructed from
national registries using International Classification of Diseases
(ICD), Social Insurance Institute (KELA) drug reimbursement and
ATC codes linked with DNA data.RESULTS
Clinical Characteristics
The two male subjects were referred to the endocrinologist due to
mild growth retardation and normal TSH, but low serum fT4
concentrations. They were both diagnosed with CeH between the
age of 5 – 6 years. The index case (patient #1) and his brother
(patient #2) had normal serum TSH and low fT4 values prior the
diagnosis (Figures 1A, B). Both cases had blunted TSH response
(DTSH, <1.6) to TRH stimulation (Figure 1D), no interfering
antibodies in TSH or TH assays, and the TG or TPO antibody
tests were negative (Figure 1A, table). Secretion defects or
dysfunction of other pituitary hormones were excluded
(Supplemental Table 1). Both MRI of the head and
ultrasound evaluation of the thyroid were normal in both cases
at the time of diagnosis. Patient #1 had linear growth until the
age of 2 years, after which his height standard deviation scores
(SDS) decreased from –1 to –2.4 SD between the age 2 and 5
years (Figure 1E). His brother (#2) had similar growth
retardation prior to the CeH diagnosis. Both had delayed bone
age (2.0 - 2.3 and 0.7 years behind the calendar age) at the time of
diagnosis. There were no significant alterations in other
biochemical or metabolic variables measured including glucose,1https://finngen.gitbook.io/documentation/
2https://www.finngen.fi/en/researchers/clinical-endpoints
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factor-1, cholesterol or cortisol levels (Supplemental Table 1).
The thyroxine replacement was started promptly after CeH
diagnosis and fT4 levels returned to normal. Furthermore, the
serum TSH concentrations, although within the normal range at
diagnosis, decreased significantly in both cases after thyroxine
supplementation. A small increase in growth velocity was also
noted after the initiation of thyroxine treatment (Figure 1E).
Both brothers were born at term after a normal pregnancy
and uncomplicated birth with >9 APGAR-scores. However,
patient #1 received phototherapy for prolonged jaundice as a
newborn. The birth weight, height and head circumferences were
within average Finnish standards. Patients #1 and #2 had normal
umbilical serum TSH levels (patient #1: 11 mU/l and patient #2:
6.6 mU/l) measured at birth as a part of the CH screening
program. Both brothers reached all developmental milestones,
had normal weight gain and head growth pattern during the first
two years (Figures 1F, G), normal weight gain and development
and no further diagnoses. Both parents were healthy, had thyroid
function tests (TSH, fT4, fT3) in normal range, and negative
TPO and Tg antibody tests, when measured at the recruitment
visit. There was no positive family history for thyroid disease.
Genetic Findings
A novel frameshift variant was detected in hemizygous state in
exon 1 of the IRS4 gene located on the X chromosome
(X:107977861; NM_003604.2) of the affected male proband
(Figure 1H). The detected variant had a 1bp insertion
(c.1712_1713insT), which leads to a frameshift mutation
(p.Gly572Trp fs*32, amino acid sequence listed in
Supplemental Figure 1), premature stop codon and strongly
truncated protein (Figure 1H). This variant most likely degrades
through nonsense-mediated decay and is not present in the
gnomAD and dbSNP databases. Confirmation and co-
segregation of the mutant in the family was performed using
Sanger sequencing. The same variant was also found in the DNA
of the affected brother and the mother, who was a healthy carrier
(Figures 1A, C). No other pathogenic variants associated with
CeH were detected in the clinical exome.
Exploring IRS4 Mutations
in the FinnGen Study
To explore the role of IRS4 in both hypothyroidism and across
the medical spectrum, we used the large FinnGen population
study which in release 5 had integrated genome-wide genotyping
and extensive medical history data from 218 792 Finns. We
searched for any rare loss-of-function (LoF) or damaging
missense mutations (Table 1) and found no LoFs. Of note, the
only rare predicted damaging missense variant observed
(rs766893547, p.Arg8His) was carried by two female congenital
hypothyroidism cases (an enrichment odds ratio of 6.7 compared
to all females, p = 0.03). Furthermore, another variant
(rs1801164) had significant association to renal failure
(Supplemental Figure 2).
We then surveyed the IRS4 locus to see if any medical
phenotypes might be associated to this genomic region. This
was done by evaluating the DNA variants at the IRS4 locus inMay 2021 | Volume 12 | Article 658137







FIGURE 1 | Pedigree, thyroid function tests, growth charts and chromatograms of the family with two brothers diagnosed with isolated central hypothyroidism
(CeH). (A) Pedigree, serum TSH, fT4, fT3 and TPO antibody (S-TPOAb) concentrations in parents and their offspring. Bolded values indicate concentration below the
reference range. (B) Follow-up graph of the serum TSH and fT4 concentrations in the affected cases before and after the thyroxin replacement therapy. Blue and
orange rectangles show fT4 and TSH reference ranges, respectively. (C) Chromatograms of the IRS4 sequence flanking the mutation in mother (1A), father (1B), and
the two patients #1 and #2 presenting CeH. Black arrows show the position of thymidine insertion. (D) TSH response in TRH stimulation test of the affected cases,
gray area indicates a range of normal TSH response. (E) Growth (height SD) and (F) weight (%) curves of the affected siblings: #1 (red) and #2 (blue). Arrows indicate
the time of CeH diagnosis and the start of thyroxine treatment. The green dots and lines show bone age determined at the indicated calendar age using the Tanner-
Whitehouse method, and dotted line shows the expected length calculated from the parents´ heights. (G) Head circumference in affected siblings carrying IRS4
mutation during the first 2 years. Light blue lines show SD values. (H) Location of the IRS4 frameshift mutation detected in this study (marked with red triangle),
premature stop codon (indicated with star) previously published (6) IRS4 mutations (marked with red lines). The location of IRS4 gene shown is based on the
GRCh37.p13 primary assembly.Frontiers in Endocrinology | www.frontiersin.org May 2021 | Volume 12 | Article 6581374
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obtained from national registries linked with the DNA data.
Across all 2925 phenotypes studied in the FinnGen project, the
strongest associations discovered were with thyroid disorders
(p = 1.3x10-7) and hypothyroidism (p = 8.3x10-7), which were
associated to a rare Finnish-enriched haplotype (tagged by SNP
rs1452561670 20 kb downstream of IRS4) (Supplemental Figure
2). This haplotype spans a roughly 500 kb interval within which
IRS4 is the only documented protein-coding gene.DISCUSSION
Isolated central hypothyroidism (CeH) in children is rare and
challenging to diagnose clinically. It has a multifactorial etiology
and a small proportion of cases that are due to gene mutations.
Therefore, the etiology for several cases remains unsolved.
Currently, mutations in five different genes have been shown
to associate with CeH. In this study, we describe a genetic,
clinical and biochemical characterization of a family with two
brothers presenting CeH at the age of 5 years. Furthermore, an
evaluation of candidate gene variants for isolated CeH and their
putative association to other phenotypes in a national genetic
database was performed. In the present study, both affected cases
with a novel frameshift mutation in an X-linked IRS4 gene were
shown to have normal umbilical TSH measured at newborn
screening and normal psychomotor development. However,
their growth started to slowly decline 2-3 years prior to the
diagnosis of CeH, which prompted the investigations. The TSH
response was blunted in the TRH-test and TSH levels declined
from mid-normal to low- normal after start of the thyroxine
replacement. The mother was a healthy carrier with normal TSH
and also fT4 concentrations at the upper normal range. The data
from this family supports the pathogenic role of IRS4 in isolated
central hypothyroidism and the cases showed no obvious
additional phenotypes. Furthermore, the candidate gene
analysis using the FinnGen database showed an association
between the IRS4 locus and thyroxine purchases.
So far, only one study has reported the association of CeH with
pathogenic mutations in IRS4 (6). Heinen et al. described five
families and seven affected male patients with four different
mutations in the IRS4 gene. Most of those patients were detected
at birth vianeonatal screeningwhich can identify both primary and
CeH (13). Unfortunately, CeH is not usually detected in congenitalFrontiers in Endocrinology | www.frontiersin.org 5hypothyroidism (CH) screening programmes, which are generally
targeted to detect themore prevalent primaryCHusingTSH-based
screening (4, 14). However, in some countries with T4-based
screening programmes CeH can be detected at birth and potential
neurodevelopmental disabilities can be therefore prevented. The
importance of such screening was recently demonstrated in a study
by Lanting et al. (15), which showed a relatively high (1 in 16 404)
occurrence of CeH. Moreover, this finding is also supported by the
fact that the clinical recognition of isolated CeH can be challenging
without the classic symptoms, such as hypoglycemia, jaundice and
micropenis observed typically in panhypothyroidism (2). Thus the
debate continues whether the screening should also detect central
CHcontinues (15, 16). InFinland, TSH-based screening is used and
the CeH cases have not been routinely detected (17). The two cases
described in our study, show that the impaired IRS4 function does
not necessary lead to severe CH, as the boys´ development, growth
and head growth for the first 2 years was normal. Similarly, in the
study fromHeinen et al. (6) they report a male case diagnosed with
CeH at the age of 12, originally evaluated because of short stature
and delayed tooth eruption but otherwise normal development.
This suggests that a significant degree of compensation can occur
either in the regulation of the growth during the infancy and
childhood phase or at the thyroid axis level. In fact, the fT3 levels
in our patients were normal or only slightly below the reference
range, and normal among the patients described in the previous
study (6). In the previously described IRS4mutation cases the TSH
response to the TRH-test was blunted in six of seven male IRS4
mutation carriers, similar to that seen in our patients. The value of
the TRH-test in the diagnosis of CeH with multiple etiologies has
been shown to be controversial (18, 19), and the response can be
affected by multiple factors such as initial TSH level, age, weight or
nutritional state (20–22). However, the blunted TSH response seen
in our CeH cases and the previously described IRS4 mutation
carriers suggest that the IRS4 is needed for the proper signaling of
the TRH. The IRS4 gene codes for a cytoplasmic protein which
interactswith tyrosine kinase receptors andmediates their signaling
(23). It has been shown to be expressed in the hypothalamus, but
also has been found in several other tissues including the pituitary,
thyroid and ovaries (10). IRS4 knock-out mice exhibit mild
metabolic differences including lower blood glucose levels,
impaired glucose tolerance and decreased fertility (24).
Additionally, IRS4 female knockout mice have decreased Tshb
mRNA expression in the pituitary, but no altered serum TSH or
thyroid hormone concentrations. In contrast, the lack of IRS4TABLE 1 | IRS4 missense variants in the FinnGen-database.
Location source rsid HGVSp poly-phen N(m/f) fin.AF nfsee.AF
23:108733710:G:C I rs1801164 p.His879Tyr U ND 0.14554 0.2104144
23:108734099:C:T C rs774511400 p.Arg749Lys U 32/124 0.00049966 0
23:108735030:T:A I rs137853896 p.Ser439Cys B ND 0.0063782 0.00043206
23:108735113:C:T I rs41307415 p.Arg411Gln B ND 0.030372 0.05821377
23:108736245:G:A I rs1801162 p.Leu34Phe B ND 0.030347 0.05845302
23:108736257:C:A C rs769861641 p.Val30Leu B 12/75 0.00025102 0
23:108736322:C:T C rs766893547 p.Arg8His PB 25/110 0.00031291 0May 2021 | Volume 12 | AIRS4 Missense variants in the FinnGen-database. Variant source; I (imputed) or C (variant detected from chip); rsid. rs number; HGVSp, the HGVS protein sequence name (genome build
38); Polyphen: U, unknown, B, benign; PB, probably damaging; N, number of males (m) and females (f); ND, not detected; fin.AF, allelic frequency in Finnish; nfsee, non-Finnish-non-
Swedish-non-Estonian European.rticle 658137
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mechanisms remainunclear. ImpairedTSHpulsatile secretionmay
be linked to leptin action (6) that has been shown to participate in
TRH response (25) and its action is partially mediated via
IRS proteins.
A limitation of our study is the lack of functional test of the
mutation pathogenicity. However, IRS4mutation segregation in the
family, the frameshift alteration leading to premature stop codon
strongly support the pathogenicity of the mutation. Since the fine
regulation of thyroid function via hypothalamus and pituitary
seems to differ between human and mice (6) further functional
studies, for example using induced human pluripotent pituitary cell
lines, are warranted to elucidate the detailed mechanisms.
Using FinnGen data we could not identify new LoF
mutations. However, one rare predicted damaging missense
variant (rs766893547, p.Arg8His) was present in two females
with a congenital hypothyroidism diagnosis. Furthermore, an
association of the variant rs1452561670 to the thyroid endpoint
category was observed. Although these associations include cases
with central isolated hypothyroidism (ICD code E23.05), they
may also indicate primary thyroid diseases.
To our knowledge, general association of the IRS4 variants to
thyroid diseases has not been previously described in GWAS
studies or genetic databases. However, our observation of a
Finnish-enriched haplotype spanning IRS4 would not be
detectable outside of a large Finnish study. This haplotype
spans a roughly 500 kb interval within which IRS4 is the only
documented protein-coding gene.
In addition to the association to thyroid endpoint category in
FinnGen one IRS4 missense variant (rs1801164) had a significant
association to renal failure. However, no renal phenotypes were
described in humans with IRS4 frameshift mutations in the
previous publication (6). Furthermore, in our study the
creatinine values were normal and there was no sign of kidney
dysfunction in the individuals with IRS4 mutation and the family
history was negative for any kidney diseases. Therefore, the
present clinical findings do not support this database
association at least in young individuals.
In summary, our data from patients with a novel frameshift
mutation in IRS4 gene together with the observed association
between the rare IRS4 haplotype and thyroid disease risk supports
the pathogenic role of IRS4 in isolated central hypothyroidism.DATA AVAILABILITY STATEMENT
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11. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer
(IGV): High-Performance Genomics Data Visualization and Exploration.
Brief Bioinform (2013) 14:178–92. doi: 10.1093/bib/bbs017
12. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, Scalable
Generation of High-Quality Protein Multiple Sequence Alignments Using
Clustal Omega. Mol Syst Biol (2011) 7(539):1–6. doi: 10.1038/msb.2011.75
13. Kempers MJE, Van Der Sluijs Veer L, Nijhuis-van Der Sanden MWG, Kooistra
L, Wiedijk BM, Faber I, et al. Intellectual and Motor Development of Young
Adults With Congenital Hypothyroidism Diagnosed by Neonatal Screening.
J Clin Endocrinol Metab (2006) 91:418–24. doi: 10.1210/jc.2005-1209
14. Cherella CE, Wassner AJ. Update on Congenital Hypothyroidism. Curr Opin
Endocrinol Diabetes Obes (2020) 27:63–9. doi: 10.1097/MED.0000000000000520Frontiers in Endocrinology | www.frontiersin.org 715. Lanting CI, Van Tijn DA, Loeber JG, Vulsma T, De Vijlder JJM, Verkerk PH.
Clinical Effectiveness and Cost-Effectiveness of the Use of the Thyroxine/
Thyroxine-Binding Globulin Ratio to Detect Congenital Hypothyroidism of
Thyroidal and Central Origin in a Neonatal Screening Program. Pediatrics
(2005) 116:168–73. doi: 10.1542/peds.2004-2162
16. Price A, Weetman AP. Screening for Central Hypothyroidism is Unjustified.
Br Med J (2001) 322:798. doi: 10.1136/bmj.322.7289.798
17. Virtanen M, Perheentupa J, Mäenpää J, Pitänen L, Pikkarainen J. Finnish
National Screening for Hypothyroidism. Eur J Pediatr (1984) 143:2–5.
doi: 10.1007/bf00442737
18. Mehta A, Hindmarsh PC, Stanhope RG, Brain CE, Preece MA, Dattani MT. Is
the Thyrotropin-Releasing Hormone Test Necessary in the Diagnosis of
Central Hypothyroidism in Children. J Clin Endocrinol Metab (2003)
88:5696–703. doi: 10.1210/jc.2003-030943
19. Van Tijn DA, De Vijlder JJM, Vulsma T. Role of the Thyrotropin-Releasing
Hormone Stimulation Test in Diagnosis of Congenital Central
Hypothyroidism in Infants. J Clin Endocrinol Metab (2008) 93:410–9.
doi: 10.1210/jc.2006-2656
20. Aizawa T, Koizumi Y, Yamada T, Tawata M, Nagata H, Izumiyama T, et al.
Difference in Pituitary-Thyroid Feedback Regulation in Hypothyroid Patients,
Depending on the Severity of Hypothyroidism. J Clin Endocrinol Metab
(1978) 47:560–5. doi: 10.1210/jcem-47-3-560
21. Leslie RDG, Isaacs AJ, Gomez J, Raggatt PR, Bayliss R. Hypothalamo-
Pituitary-Thyroid Function in Anorexia Nervosa: Influence of Weight Gain.
Br Med J (1978) 2:526–8. doi: 10.1136/bmj.2.6136.526
22. Rijks J, Penders B, Dorenbos E, Straetemans S, Gerver WJ, Vreugdenhil A.
Pituitary Response to Thyrotropin Releasing Hormone in Children With
Overweight and Obesity. Sci Rep (2016) 6:1–6. doi: 10.1038/srep31032
23. Wauman J, De Smet AS, Dominiek Catteeuw DB, Tavernier J. Insulin
Receptor Substrate 4 Couples the Leptin Receptor to Multiple Signaling
Pathways. Mol Endocrinol (2008) 22:965–77. doi: 10.1210/me.2007-0414
24. Fantin VR, Wang Q, Lienhard GE, Keller SR. Mice Lacking Insulin Receptor
Substrate 4 Exhibit Mild Defects in Growth, Reproduction, and Glucose
Homeostasis. Am J Physiol - Endocrinol Metab (2000) 278:127–33.
doi: 10.1152/ajpendo.2000.278.1.e127
25. Guo F, Bakal K, Minokoshi Y, Hollenberg AN. Leptin Signaling Targets the
Thyrotropin-Releasing Hormone Gene Promoter in Vivo. Endocrinology
(2004) 145:2221–7. doi: 10.1210/en.2003-1312
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Patyra, Makkonen, Haanpää, Karppinen, Viikari, Toppari, Reeve
and Kero. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) and the copyright owner(s) are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.May 2021 | Volume 12 | Article 658137
